Unigestion Holding SA Has $38.96 Million Stock Position in Johnson & Johnson (NYSE:JNJ)

Unigestion Holding SA lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 21.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 269,424 shares of the company’s stock after selling 75,553 shares during the period. Johnson & Johnson makes up 2.2% of Unigestion Holding SA’s investment portfolio, making the stock its 10th largest holding. Unigestion Holding SA’s holdings in Johnson & Johnson were worth $38,964,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Principal Financial Group Inc. raised its position in shares of Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after purchasing an additional 329,473 shares during the last quarter. United Bank raised its holdings in Johnson & Johnson by 5.6% in the third quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after buying an additional 202 shares during the last quarter. EP Wealth Advisors LLC lifted its stake in shares of Johnson & Johnson by 8.9% in the third quarter. EP Wealth Advisors LLC now owns 544,719 shares of the company’s stock worth $88,277,000 after buying an additional 44,526 shares in the last quarter. iA Global Asset Management Inc. grew its holdings in shares of Johnson & Johnson by 27.2% during the third quarter. iA Global Asset Management Inc. now owns 319,787 shares of the company’s stock valued at $51,825,000 after buying an additional 68,372 shares during the last quarter. Finally, Goldstream Capital Management Ltd bought a new stake in shares of Johnson & Johnson during the third quarter valued at approximately $951,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $153.03 on Friday. The stock has a 50-day simple moving average of $159.75 and a two-hundred day simple moving average of $155.84. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The firm has a market capitalization of $368.77 billion, a PE ratio of 23.01, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the firm posted $2.29 EPS. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Activity

In related news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several analysts have commented on the company. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research note on Friday, January 24th. Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Leerink Partners reduced their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.